Cardiovascular Imaging Systems
This article was originally published in The Gray Sheet
Plans to introduce its MicroRail 3.2 French coronary imaging catheter in the second quarter of the year. Marketing of the device, cleared via 510(k) in July 1992, was delayed while the company concentrated its efforts on the MicroView 2.9 French common lumen coronary imaging catheter, which was cleared last June and began shipping in August. The price of the MicroRail will be "comparable" to the $625-$650 charged for MicroView, the company says
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.